跳至主要内容
临床试验/NCT01930071
NCT01930071已完成不适用

PQ Bypass Guide Wire Delivery System for Femoropopliteal Bypass

Endologix1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
4
试验地点
1
主要终点
Primary Patency

研究概览

简要总结

To assess the safety of performing a percutaneous fem-pop bypass using the PQ Bypass Guidewire Delivery System and commercially available stent grafts.

详细描述

Multi-center, single-arm first-in-man study utilizing the PQ Bypass Guide Wire Delivery System to access, deliver guidewires and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Willing and able to provide informed consent
  • Age 18 or older
  • Rutherford Classification of 3-5
  • Lesions ≥10cm in length considered to be:
  • Chronic total occlusion (100% stenosis)
  • Diffuse stenosis (>50% stenosis) with moderate to heavy calcification
  • In-stent restenosis (>50% stenosis)
  • Proximal and distal target vessels are 4.8 - 7.5 mm in diameter
  • Orifice and proximal 1cm of SFA is patent
  • Patent popliteal artery 3cm proximal to tibial plateau
  • At least 1 patent tibial artery to the foot
  • Patent femoral vein

排除标准

  • History of deep vein thrombosis
  • Has a known sensitivity or allergy to contrast materials that cannot be adequately pre-treated
  • Has a known sensitivity or allergy to aspirin, heparin or anti-platelet medications
  • Documented in-sensitivity to anti-platelet medication
  • Has a known or previous coagulopathy
  • Pregnant or lactating
  • Untreated flow-limiting aortoiliac occlusive disease
  • Has renal failure (GFR < 30mL/min)
  • Major distal amputation (above the transmetatarsal) in the study or non-study limb
  • Patient has had a procedure on the target limb within 30 days
  • Previous bypass surgery on the target limb
  • Bypass length required is greater than 35cm

结局指标

主要结局

Primary Patency

时间窗: 30 days

次要结局

未报告次要终点

研究者

发起方
Endologix
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验